RELATIONSHIP BETWEEN BODY MASS INDEX AND PATOHISTOLOGICAL FEATURES OF THYROID CANCER

Overview

Journal Acta Clin Croat

Specialty General Medicine

Date 2023 Jul 26

PMID 37492362

Authors

Zeljko Zubcic

Hrvoje Mihalj

Anamarija Sestak

Andrijana Vceva

Ivan Abicic

Tihana Mendes

Affiliations

Soon will be listed here.

Abstract

Available studies report conflicting results on the association of body mass index (BMI) and pathohistological features of thyroid cancer. This study aimed to investigate the relationship between BMI and the pathohistological features of different thyroid cancer types. We analyzed the following data from 95 patients with thyroid cancer: age, gender, BMI, pathohistological characteristics of cancer (tumor size, multifocality, lymphovascular invasion, extrathyroidal invasion) and the presence of regional metastases. The BMI of all patients with thyroid cancer was 27.1 ± 4.2. Significantly more patients with obesity class I had cancer size less than 2 cm (p = 0.02). There is a significant association between BMI and extrathyroid invasion (p = 0.03; OR, 1.18), but not with lymphovascular invasion, tumor size, and multifocality. We can conclude that although obesity is a risk factor for the development of thyroid cancer, higher BMI is only partially associated with more aggressive pathohistological features of thyroid cancer.

References

Landa I, Robledo M . Association studies in thyroid cancer susceptibility: are we on the right track?. J Mol Endocrinol. 2011; 47(1):R43-58. DOI: 10.1530/JME-11-0005. View

Campenni A, Trimarchi F, Baldari S . Comment on: Lack of association between obesity and aggressiveness of differentiated thyroid cancer. J Endocrinol Invest. 2018; 42(1):107-108. DOI: 10.1007/s40618-018-0970-5. View

Chen A, Jemal A, Ward E . Increasing incidence of differentiated thyroid cancer in the United States, 1988-2005. Cancer. 2009; 115(16):3801-7. DOI: 10.1002/cncr.24416. View

Zubcic Z, Sestak A, Mihalj H, Kotromanovic Z, Vceva A, Prpic T . The AsSociation Between Type 2 Diabetes Mellitus, Hypothyroidism, and Thyroid Cancer. Acta Clin Croat. 2021; 59(Suppl 1):129-135. PMC: 8212611. DOI: 10.20471/acc.2020.59.s1.17. View

Engeland A, Tretli S, Akslen L, Bjorge T . Body size and thyroid cancer in two million Norwegian men and women. Br J Cancer. 2006; 95(3):366-70. PMC: 2360634. DOI: 10.1038/sj.bjc.6603249. View

Kitahara C, McCullough M, Franceschi S, Rinaldi S, Wolk A, Neta G . Anthropometric Factors and Thyroid Cancer Risk by Histological Subtype: Pooled Analysis of 22 Prospective Studies. Thyroid. 2016; 26(2):306-18. PMC: 4754509. DOI: 10.1089/thy.2015.0319. View

Jung Y, Oh C, Kim Y, Jung K, Ryu J, Won Y . Long-term survival of patients with thyroid cancer according to the methods of tumor detection: A nationwide cohort study in Korea. PLoS One. 2018; 13(4):e0194743. PMC: 5901988. DOI: 10.1371/journal.pone.0194743. View

Rebai M, Kallel I, Charfeddine S, Hamza F, Guermazi F, Rebai A . Association of polymorphisms in estrogen and thyroid hormone receptors with thyroid cancer risk. J Recept Signal Transduct Res. 2009; 29(2):113-8. DOI: 10.1080/10799890902845682. View

Sado J, Kitamura T, Sobue T, Sawada N, Iwasaki M, Sasazuki S . Risk of thyroid cancer in relation to height, weight, and body mass index in Japanese individuals: a population-based cohort study. Cancer Med. 2018; 7(5):2200-2210. PMC: 5943544. DOI: 10.1002/cam4.1395. View

10.

Yeo Y, Ma S, Hwang Y, Horn-Ross P, Hsing A, Lee K . Diabetes mellitus and risk of thyroid cancer: a meta-analysis. PLoS One. 2014; 9(6):e98135. PMC: 4057085. DOI: 10.1371/journal.pone.0098135. View

11.

Ahmadi S, Pappa T, Kang A, Coleman A, Landa I, Marqusee E . Point of Care Measurement of Body Mass Index and Thyroid Nodule Malignancy Risk Assessment. Front Endocrinol (Lausanne). 2022; 13:824226. PMC: 8873520. DOI: 10.3389/fendo.2022.824226. View

12.

Rajoria S, Suriano R, Shanmugam A, Wilson Y, Schantz S, Geliebter J . Metastatic phenotype is regulated by estrogen in thyroid cells. Thyroid. 2010; 20(1):33-41. PMC: 2833180. DOI: 10.1089/thy.2009.0296. View

13.

Economides A, Giannakou K, Mamais I, Economides P, Papageorgis P . Association Between Aggressive Clinicopathologic Features of Papillary Thyroid Carcinoma and Body Mass Index: A Systematic Review and Meta-Analysis. Front Endocrinol (Lausanne). 2021; 12:692879. PMC: 8279812. DOI: 10.3389/fendo.2021.692879. View

14.

Kim H, Kim N, Choi J, Sohn S, Kim S, Jin S . Associations between body mass index and clinico-pathological characteristics of papillary thyroid cancer. Clin Endocrinol (Oxf). 2012; 78(1):134-40. DOI: 10.1111/j.1365-2265.2012.04506.x. View

15.

Kim J . The clinical importance of overweight or obesity on tumor recurrence in papillary thyroid carcinoma. Gland Surg. 2022; 11(1):35-41. PMC: 8825508. DOI: 10.21037/gs-21-695. View

16.

Zhang W, Bai X, Ge H, Cui H, Wei Z, Han G . Meta-analysis in the association between obesity and risk of thyroid cancer. Int J Clin Exp Med. 2015; 7(12):5268-74. PMC: 4307477. View

17.

Shin A, Cho S, Jang D, Abe S, Saito E, Rahman M . Body Mass Index and Thyroid Cancer Risk: A Pooled Analysis of Half a Million Men and Women in the Asia Cohort Consortium. Thyroid. 2021; 32(3):306-314. PMC: 8971972. DOI: 10.1089/thy.2021.0445. View

18.

ONeill R, Abd Elwahab S, Kerin M, Lowery A . Association of BMI with Clinicopathological Features of Papillary Thyroid Cancer: A Systematic Review and Meta-Analysis. World J Surg. 2021; 45(9):2805-2815. DOI: 10.1007/s00268-021-06193-2. View

19.

Dal Maso L, La Vecchia C, Franceschi S, Preston-Martin S, Ron E, Levi F . A pooled analysis of thyroid cancer studies. V. Anthropometric factors. Cancer Causes Control. 2000; 11(2):137-44. DOI: 10.1023/a:1008938520101. View

20.

Samanic C, Chow W, Gridley G, Jarvholm B, Fraumeni Jr J . Relation of body mass index to cancer risk in 362,552 Swedish men. Cancer Causes Control. 2006; 17(7):901-9. DOI: 10.1007/s10552-006-0023-9. View